Clinical utility of YKL-40 for understanding pathophysiology of obstructive airway disorders
Serum and sputum YKL-40 may reflect distinct clinical features in obstructive airway disorders. Serum YKL-40 may provide beneficial information on predicting obstructive neutrophilic inflammation and exacerbations, whilst sputum YKL-40 may offer valuable insights for evaluating ongoing symptoms. Concomitant measurement of YKL-40 in serum and sputum might be more useful than individual measurement.
Authors
- Masami Kikuchi
- Xintao Wang (ORCID: https://orcid.org/0009-0002-8213-0556)
- Yoko Shibata (ORCID: https://orcid.org/0000-0003-1794-0026)
- Yoshinori Tanino (ORCID: https://orcid.org/0000-0003-2384-601X)
- Hiroyuki Minemura (ORCID: https://orcid.org/0000-0001-8710-1960)
- Kentaro Kazama (ORCID: https://orcid.org/0000-0002-8995-0357)
- Ryuichi Togawa
- Ryuki Yamada
- Yasuhito Suzuki (ORCID: https://orcid.org/0000-0002-5177-4079)
- Takefumi Nikaido (ORCID: https://orcid.org/0009-0000-6580-5262)
- Riko Sato
- Junpei Saito (ORCID: https://orcid.org/0000-0002-9876-1160)
- Kenya Kanazawa
- Mami Rikimaru
- Rina Harigane
- Yuki Sato (ORCID: https://orcid.org/0000-0002-8986-8388)
- Natsumi Watanabe
- Suguru Sato (ORCID: https://orcid.org/0000-0001-9675-9051)
- Atsuro Fukuhara
- Koshi Saito
- Takashi Umeda (ORCID: https://orcid.org/0000-0001-9085-7355)
- Hikaru Tomita
Institutions
- Fukushima Medical University (JP)
Publication Details
- Journal
- Allergology International
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1016/j.alit.2025.05.004
- Primary Topic
- Studies on Chitinases and Chitosanases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharmaceuticals Corporation
- Japan Society for the Promotion of Science London